!
 (Basic clinical study designs)

. 




 
  










  (Drug Information Service) 01

2 


345
36 
  7685
9 :
 
7; 70
 
2<0 76345  2= >2:?76

@2AB4 

0C5 (Primary literature) G@2H

H  
(Original article) ;; 456 

85



  H@4 
J46

 H
 7
:08
@K H
46


H;B24
= <04= J 
B4
:0 ;B24
= <00L
<?46 J54

4H
M


  
J

46

H  
22 34

K 4B2
N2 6 ;B242H6

3 H



K  3@M

507
H 
2 234  

J76<? 73@M
456K34
76

2
MH6 J@K34
76
H 2;A
64N ?
M

  
 !
;!5<
6 !
 
J7601
2 K B4
1. 345
6 !
! (retrospective study) 01

507
@K 2 
B40



B4:646 2H=
@K 7=
?
 
B48;P 2?3@M
H
 
4?
?
502 1

@K
507
M85 H4 H;0R> 2 
A34524 H= 
A345 46 <6
J54 ?  ?B24
<65
 6
 4
345 46 2 44J H 850S9?

85HH44J 345
4?34850S 9?
J 850S   0RHH:
2=
@K G@24 H0R>

B24  ?B24
4

B24 H  
H= 34854= J 

@K 7A3454
  = 

@K 2<6 
JA345
B48;P 7<0
3 
 <? 46 6
4
@K 4
<6;@0
 H
 (adverse effect) 24 H?3@M


4

?2=  (rare incidence) 
B44 H?3@M
764



? 8 (long term
adverse effect) 01


Past

Present
Time period

 1 
    (retrospective study)

2. 345
6 !>
 (prospective study) 01

@K 2
A3452
H2H
?3@M

4
 ?
502 2
@K
507
M34? B4
A345<03 

H 
J447

A3459?P2 
J0V4
4 (bias) 2 
J?3@M
<? 


0V4
4 6



00X(blinding) 

:6(randomization) 01

7
A345<03 
 H= A
345<?
J
 6
A34574
 34= H?= 

@K
507
MB4 0R> 
B24
<6
 
J? 850S
J
:
<?(loss to follow-up) 7 6 H 6 5

@K 46 

@K 7A345<03 
 6

@K ?
0
P874
<6;@0
 

M

0
 randomized controlled trial
Present

Future
Time period

 2 
  %&   (prospective study)

  
 !
;!5< ?@

76
507
@K
M;H
  K34
:
@K 3485H

@K 2
85H3 <0:=
@K H?01

@K ?4 (experimental study) 76
@K 285H<6<?
3 <0:= 
 2;76 7H?
@3456
M
H?01

@K  (observational
study) ?
502 3
'())
(clinical study)


-)1
2
(observational study)


-)45
(descriptive study)
- cross-sectional study
- longtitudinal study
- retrospective study


-)'.
(experimental study)

@K 

(analytical study)
- cross-sectional study
- cohort study
- case-control study

randomization

 A 3 K
@K  


non-randomization

345

; (observational study)

@K  (observational study) 85HH=
A
@345
B4? 8;P 2
H

B44J J@0RHH6 N 2 2 34
@K 9?85H H<602
70
B4234
?
H


B242 234

K 
B4
 
:60

2=
@K
@K  


507

@K   
J76<? 2 0
 B4
1. 345
D<
 (descriptive study)

@K H ;


6
>6H01


  : (prevalence) 74:

(incidence) 349
 0RHH 0

6 N 201
K2 234
?9
6
4 : ; BM4 
8
HH
= 
4

5034
;


9?<6

 0
345
6 :60

2
@K 7664<?01
3 K


@K  H:? ? 
@2 (cross-sectional study)  
M

01
case report
B401

@K 2 H=

850S;
? 
B4 case-series B4
@K 2H =

850S
 6 1 
3@M
<0 H7?345?J;


(descriptive statistics) 6
6 _2

7 70
0

34 physiological parameter 2;
P 8

434850S2
?4
<6;@0
 01

8H
@K 0

M <6 
J01
C
;B42
0

:6 34 6
?
0
P87 04? 6
>6 case report 
B4
case-series H01


224
<6;@ 0



@K ;


201

64
B2434:6
?

@201

 
@2 N
(longtitudinal study)
46 
?54

?9
7
G4
34850S2 01
9
 
(incidence)


@K ;


9?A3454

46 
@K  :34850S201
9
<3B4?44
4:


 1

9
;  

 0

K 
60a 2545
2. 345

 E (analytical study)

@K 
  J:0
 ;B24
 0
8
@K
6 :66 N G@276
4401
3 K ?
M
Cross-sectional study
01

@K  ;
P 346 6 N  H:?
@234 
B4

 2 = 
? 
B401


@K 
?2
2
H 0

:6>6;:6?  H:?
@234 
B4

 2 = 
?

@K 
?
M  = 

@K 2

H _9
 7
@K BM4

0
?A
4B2
N 6


@K  ;
P
6  pressure sore risk score 
?78?

Cohort study

@K 7 cohort study 01

@K 
 (Analytical study) 201

@K 6
8;P (outcome)  ;
P 0RHH2
H@K (exposure) 
B4<6
@K 7 cohort HfV
0

285H<?
?B4< 9?:60

2
H
M01
:6 0

2 <6?9

B4
:
 285H
H (event-free) H
M
? ?5 6 :60

?:
 285H 
H
B4<6
9?2<0
= cohort J:0
 ;B24
1.  3
?340R> 
B44:

?9
 (incidence) 
B4 4:

  (mortality)

B4 2 (risk)
2.   ;
P
6 
  2
B40
P89?H0
6 4

?8;P 6
?9


B4<6?9

6 :62<?
 (exposed) 7<6<?
 2@K
(unexposed) 76 

B4<6
 
M
@K 7 cohort study 4 HK2<66
K34
@K 

(analytical study) 7601

@K ;


(description study) G@2J:0

 ;B24

 
B4
0
 4:
 34
?8;P 34:6
:6
@2 2
H 6

@K H 
:6850S
B4
Framingham
C Massachusetts ;B24 4:
 

?9
 
BM4H  (The Framingham
Heart Study)

 A 4
@K 7 Cohort 
?6 N

 345
J cohort study

@K H 7 cohort 4 H7644<?01
2 7 B4
1. Prospective cohort
Prospective cohort 
B4 concurrent cohort  J@ 852=
@K H
2A3452

0RHH2 (exposure) 

B4<60RHH2 (not exposure) 
3?
2
2 =
@K 7
;H

?8;P 
:6 0

2
HB24 86
<0
4
 ?
502 4 ;B2444:
 34
9
6 ?
4;? 0R> 2;34
@K 7
M B4
 2



? 
?8;P

:60

4 HH= 01
40
 

= H H=

 7
5>340

2 @K

6 2 =
@K
46 
@K  ;
P 34
 NSAIDs 
? Dyspepsia 7 Ulcers ?
502 5


2
Dyspepsia and ulcers


 NSAIDs
No dyspepsia and ulcers

Dyspepsia and ulcers

<6
 NSAIDs
No dyspepsia and ulcers

Present

Future
Time period
 5
@K 7 prospective cohort

2. Retrospective cohort
Retrospective cohort  J@ 852=
@K HA345
4?H 76345 6
7
@
 
7; 
B44 H<?345H 
0
 01

2 
0HR H2 (exposure) 
B4<6
0RHH2 (not exposure) 34:60

2@K 
4?64
2850SH?9

B48;P 7?8;P
2?3@M

B4<6
6 J? H
J@0RHH:
34?34
@K 7
M B4 H6?34H= ?
?

 24? 850S 01




prospective cohort
46 
@K  ;
P
6 
 warfarin 

 
?
?5
850S 54 : ?

502 6

2

Osteoporotic Fracture

<?
 warfarin 

 
NO osteoporotic Fracture
Osteoporotic Fracture

<6<?
 warfarin

NO osteoporotic Fracture

Past

Present
Time period
 A 6
@K 7 retrospective cohort


<
345 cohort

@K 7 cohort 01

@K 9?
2H :602 <601
9
 ? H

B4<6
0RHH2 ;B24

?9

6 H@ 
J44:
 34
?9

:627 <60RHH
2<?
4H
M  
J0
 4: 
 349
6 :620HR H294 ?9
501
2
6 34:62<60HR H2 6 2<?H01
6 ;P 2
6  2;P (relative risk: RR) G@2
<?H 4

?9

6 :62<?
0RHH2:6<2 6<?
0RHH2  0

9?
=
H 82<?

 2x2 ?
2 1

2 1 
 2x2 

@K 7 cohort

Exposure

Outcome/Disease



4:
 ?9


a+b

a/(a+b)

c+d

c/(c+d)

?9


<6?9


:620RHH

:62<60RHH

4:
 349

:6 20RHH2

H=


201
9

:620HR H2
H=


2<?
0RHH2M ?

4:
 349

:6 2<60 RHH2

a / (a+b)

H=


201
9

:620HR H2
H=


2<?
0RHH2M ?

 2;P (RR)

c / (c+d)

4:
 349

:6 20RHH2
4:
 349

:62<60RHH2

a / (a+b)
c / (c+d)

46 
@K 7 cohort ;B24  ;
P
6 
5:
27
?9
4?B4?H
(coronary heart disease: CHD)

Exposure

Outcome/Disease
?9

CHD

<6?9

CHD



4:
 ?9


:65:
2

84

2916

3000

84/3000

:6<65:
2

87

4913

5000

87/5000

H 46  
J  2 ;P (RR)

84/3000
87/5000

1.6

6 RR = 1.6   6 8525:

2 2H2 ?9
4?B4?H01
1.6 6 34852<65
:
2

6 relative risk (RR) 

B4 risk ratio
MH4J@0
 
B4 
:
7
34 ;
P
6 
exposure  outcome J 6 RR 76 H 1  6 <
A  6  ;
P
M
 G@26 RR
01
<?M 7  
  (RR > 1) H  6 J 80RHH2H64?9

9?0RHH24 H01
 :34
?9
 76
 H  6 J 80RHH2H6?

?9

B40V4
<6?9

M
<? 7J 6 6  1 7?6 <6 ;
P

6 0RHH
2
?9

JA-J345
J cohort
34?
1.  
J=
4: 

?8;P <?
2.  
J=
 2;P <?9?

3.  
J@K 8340RHH2648;P <?
 
? (multiple outcome) 6

?9

4?B4?H 9

A
 9

AB24
:9;
?5
?59; H

:6 Statin 01


4. 8
@K  
6 BM4JB456 8;P

6 H ?H
<?
0RHH2
5.  
@K 

2 
8
B4
0RHH22;
4 (rare exposure)
6. 4

?0RHH2 (exposure) 
4
;

?64
H2 ?8;P 


prospective cohort

34?4
1. 0R> selectiion bias H
2<6
randomization G@268?0RHH

2. 0R>
5> 34
<0H cohort
3. <6 = 

@K 
9
2;<?
4
;
43
?46 2 ;B242H
H=

85 01
9
;;42H
=  
  
J<?
4. 4 H4

? outcome <?

285H 

6 

B4<60RHH2
5. 
 

@K

 6 H 6 5

Case-Control Study

@K 7 case-control 01

@K 74
 (retrospective study) 01

@K 2:6
  ;
P 34
8
B4<?
0RHH
?8;P 9?
2
@K 

2 8;P (9

B4
4
2
H) 
850S:6
M 6 case 0
:62<68;P (9

B44
2
H) G@2
6
control 7=
?6 :6 

76:6 <?

8
B4<?
0RHH (exposure) 
4? 64


B4<6 7
=  =
 ?6
3494 34852?9
7<?
 exposure 70
94 
34852<6?9
76<?
 exposure 6 9?
:0B4
@K 7 case-control H:6 0
?A
;B24 6
0RHH2

H@K (exposure) 01
 : (cause) 34
?8;P (outcome) 
B4<6

@K 7 case-control  = 

@K 9
24: 
  2= (rare disease) 
B401

9
2;<?
4 
;

(latency period) 6
9

A 
B24H
@K 7
MH01
PB4
46 H 
2?9
7

 A 7 K
@K 7 case-control

@K 7 case-control
MH01

@K 7?4
 (retrospective study) G@2
2
H
?B40

46 28;P 7<68;P 74
<0@K 6 
<?

8
22
H@K 6 

B4<6 
 
M
@K 7 case-control  
J= <?

2345J5A

@7<03 
 (prospective study) 
:6
(cohort) 285H? 345<03 
 B24
AHM


? 345 85H 
J=
@K  
29
 (case) 7
2<69
 (control) 7
=
@K 6 4

<?
28 (exposure)
M
76 

6 4:6
B4<6
@K K

M
6 y nested case-control study z

Nested case-control study

Nested case-control study 01

@K 
K case-control study 7601
case-control
study 2= 
cohort 
@2N  KB4
6
@K case-control study
M
456




@K 
K
MH
2?
? :6
(cohort) <0
 
@2 
B4H
H
@K
G@2= 
6 46 2 =
@K
?01
852?9
 
B4 outcome 2
H 7H@B4852?9
2

H01
:6 case 7=
:646 2B42<6?9
01
:6 control 7=
@K K
case-control  0 ?
M

@K 
K nested case-control study
MH?01

@K casecontrol  34534 cohort study ;B240
4

80RHH2
6 :6 case 7
:6 control ;B244= J 6  ;
P
6 0RHH2 79

B4<6
46 
@K  ;
P
6 
 NSAIDs (exposure) 
? oral cancer (outcome) G@2

= 345 H Cohort of Norway (CONOR)
NSAIDs
No NSAIDs

Cohort of
Norway
(CONOR)

NSAIDs

oral cancer
(case)

No oral cancer
(control)

No NSAIDs
(exposure)
Past

(outcome)
Present

Future

 A 8 K
@K 7 nested case-control

<
345 case-control

@K 7
MH
0
:6 case :6 control ;B24@K 6 0RHH276 

6 :6M4

B4<6 8
@K H44 01

 2x2 ?
2 2

2 2 
 2x2 

@K 7 case-control

Exposure

Outcome
case

Control

:620RHH

:62<60RHH



a+c

b+d



@K 7 case-control 0

46 2@K J5:6 H 
201
9
7<601
9

?
M
H@<64 H 4:
 34
?9
<? ;
<6 
J4<? 6 
2 exposed H=

6
M
H
?9
3@M
2

;76 6 
H=


01
9
6
M

2 exposed 2
6 B4 
<6 
J
 2;P (relative risk: RR) <?9?
 46 <
A  

@K 7 case-control H 
J
4J@ 2<?6

9?0
:6
2 0RHH2:6
2<60RHH2 82<?
6
odds ratio (OR) = 6 odds  J@ 94 2:

M
H?3@M
64?94 2:

M
H<6
?3@M
= 6 odds ratio  J@ 4
6
(ratio) 34 odds 

34 case-control study 01
?
M
Odds ratio (OR)

odds 34 exposure 
:6 case

odds 34 exposure 
:6 control

(a/a+c)
(c/a+c)

ad/bc

(b/b+d)
(d/b+d)

a/c
b/d

 4

B49
2@K 4

?2= (rare event) 6 OR H  RR
46 
@K  ;
P 34

:

? Endometrial cancer 
> >20:S

Exposure

Outcome
? Endometrial cancer

<6? Endometrial cancer

:62
:

77

64

:62<6
:

42

11

119

75



Odds ratio (OR) =

=
OR = 0.32   6

77 x 11
42 x 64
0.32

- 94 34? Endometrial cancer 
> >20:S
2
:

H
?01
0.32 6 34> >20:S
2<6
:


B4

JA-
A345 case-control
34?
1.  
J20R> ?
H
P

34?4
1.
B4:6:2 = <?
;
<6 
J:70


:6
@K 6 :6:<?: 
2.  2H0X?85H 2J
 ;3485 
34501
case 
B4 control H@4 H?4<?

2.  
J=
@K <?
9
2;
4/<6
64=
 2;P <?9?
7
latent period  
3. 0
? <?8
A B240

3. 8
@K 3@M
456 5
 343452
H
 
?<03 
 
B4
H 
=

@<
4?
?4
4.

H47<3345= <? 
B4<6
 
J= <?
345
 J! (experimental study)


507
@K ?4 (experimental study)
HHH?
 2
H@K G@2 JB4
6 01
intervention 76850S


= 
?
<?
 intervention  2


?
M
-



7 randomization



7<6 randomization (
B4 quasi-experimental study)

@K ?401

@K 2
?8<03 
 (prospective study) 9?=
0

4

? event 
B48;P H
<?
 intervention
6 :6@K G@2 <?
 intervention :6
control 2<6<?
 intervention 9?2<0
@K 0

MH
447
@K 
?: ;B24?4
6 N24 H?3@M
H   : ?
M
8
@K ?4H@ 
6 B24JB4

4J@0
P8

34 6<??6
@K  9?_; 46 2
@K 2 
:6 (randomization) 34

intervention 76850S
Randomized controlled trials (RCT) 01

507
@K ?42  
6 B24JB4 2:?

@K H
2 H 850S
B4853
6
@K 2 <6 event G@201
8;P H
 2
H :6
46 2 K }
?B4 (inclusion criteria 7 exclusion criteria) HJ5:6
(randomization) ;B24<?
 intervention 
?6 N (4 H 6 2 :6) 6

0
 6
placebo 
B4  
C
2 
 K 9

M
N

@K 7 randomized controlled trials 764401
2
50764N B4
1. 345 randomized controlled trials 
J cross-over

@K
507
M 853
6
@K :
H4<?
 intervention  6 1 
?

@K H2 

507
M
= 9?
76:646 4401
H=

:6 H=

intervention 285H

H 6
85H 0RHH2
H@K 2 
? A =
76:6 46 4401
2 :6 46 76:6H
<?
0RHH6 
?
G@24 H01
0RHH A 
B4 0RHH B  
 2 = 
?7=
0

8
H
M
:?0RHH?

@2G@2


M 6
; (wash out period) 7=
:6
46 <?0RHH2 6 
?
 
 2 = 
?70

GM =
H
M

= 8
@K 34:6
46 32<?
0RHH6 
?
 
 0


46 
@K ;B240

0
P ;34 70?6( A) 
850S<

0

70? 
C
( B) H@476:646 4401
2 :6 ?
50 9

F &GH%

random

IJ'KL 1 N  A

IJ'KL 2 N  B

Evaluation 1
Wash out peroid

IJ'KL 1 N  B

IJ'KL 2 N  A

Evaluation 2
 9  randomized controlled trials -). cross-over

JA!
A345 randomized controlled trials 

J cross-over
34?

 46 ;:6? 9?853
6
@K :
H<?
0RHHB4

:
  
J
? 70
8

6 :<? 7H=

46 
46
@K 7 parallel
34H= ?
 
J9

BM4

B49

2 K <6 6
M
6
9
 
9
 ?
95 76<6
 
J9

B44
2
K  3 ? 6

?BM47
 9
<3? 01


2. 345 randomized controlled trials 

J parallel group

@K
507
M
2
H
B4:646  H 0

24
@K
776
4401
:664 6 1 :6 H=

:6 64
M3@M
456H=

0RHH2850S4
@K 9?2<0J 
0RHH24
@K ; 1 
B4 2 
? A 7646 4401
2 :664 9?76:6 <?
0RHH2
6 
7
= 8
@K 3476:6 
 0


46 
@K ?
0
P ;7 04?34
 Inhaled Insulin 0


Subcutaneous Insulin 
850S 

?2 2 ?
502 10

IJ&S-'KL
&T
H-).'KL 2
(.
U2
5VW(.
U

IJ2HJ'KLFJ(.
U
random

IJ'KL%.  inhaled insulin

IJ'KL%.  subcutaneous insulin

H)
(SW
&K
'K F

502 10
@K 7 randomized controlled trials 
? cross-over


!Y;D
 Z
[



70
 J@ :K
B4:3422
B4<6   
J?<?
<? 
B47H7H
<? 7:K
B4:6
M02
70<? 6
70
?

6   <?76
M= 
  5 4 :
 ?
95
?
M=  
B4? 6
70
?
HH <?76  
5@
  
5@?  ;@
;4H642 6 N 70
?
4B2
N 6

?
@K  
C
  01

G@2 85H 
 2 ?
70
6
M44 01
6 
B436 70
6
M 76 

76:7
76:6
B4<6
7
= K276 

M 
  6 76 

446 <
 ;
P 
46 <


J;
9?2<0 
J76
6? (measurement scales) 3470
6 N 4401
2 
? B4
1. Categorical data (
B4 discrete data)
6 3470

?
MH01
767:6 7
?34 subject 6
; G@26 201
<0<? B4  
7>6
M
<6 
J 6 2456
6  7> 70

?
M 
J766444 H=


:6<?01

- 
? dichotomous : 70
2<?; 2 6 6
M
6
; ; 7;>
- 
? polychotomous : 70
2 6 2 6 6
 
 
;:P 
 4  
B4
56B4? :6 4  94 4 01


70

?
M4 H76<?446 B470
7 norminal 7 ordinal G@2H6 64<0
2. Continuous data
01
345K64
B24 <6 2M
:? 7766 ;23@M


626 
H4566 6 N
6

  01
G

6 01
1 2 3 ... G

<0
B24N <62M
:? 7
6 6 
B46  
76 
6  1  2 6  3  4 01

70

? continuous  
J764401
2 
? B4
70

? interval 7 ratio G@2 H6 64<0

4H
M4 H76
?3470
 
?
?70

4401
4 
? ?
M

G@2 
J76
?
?70

1.
 
(nominal scale) 01

?
?2 2:?  
J4 76 <?9?K34

7:66
M
<6 
J4J@ 76 
?
: ;
B4:6 <? 6
70
 
76
4401
:62
JB4 
6 
6
;:P 
 4  G@2 76 34:66
M<6 
J
:
44 01
3
B4 
J7? 76 
?
?6 
B46 ?46 <? B4 3
70

?

M<6  
  
701
345: ; 46 6

;
BM4 

7601

7601

  >
< H
4
? 4

01


2. 4
? 
(ordinal scale) 01
70
2 
J7? 76 
K24<?6  6
4
6 ?6 2 = 6 76<6 
J4
4?<? 6  76 
M
6 6 ? 70

?
M;64


H  P :3 <?76 J
  70
2 
5@6 N
?
@K 46 6

 ;

7601
<6;
;
 6
;
M?
 ?A

z
A
?46 2 A
? <6A
? <6A
?46 2

?
@K z
<6<?@ K 0
J@K P@K 4 @K 4:?@K
3.6 
(interval scale) 01
70
2 
J?
4?34:K276 
44 01

3 73
M
:  
B4  
J   5

<?  
J
: 76 
<?6  6 
B4
46 6 ? 6

4:5

?0R>> (IQ)

-10 =C, 0 =C, 32 =F, 98.6 =F 01


90, 120, 180
01


70
4:5 
J?<?01
327?J@4:55 2= 7 
J0
<?6
4:5 80 =C 56 4:5 60 =C 01

76
? 
6K_;  B4 6 35
 01
6 2
85H= 
??4 <666 5
 27H
 
B24H 6 5
 34
?6 
  7?J@6
3470

M
456 <6<6 46 6
4:5 0 =C 
B4 0 =F <6<? J@<64:5
4. 4
6
 
(ratio scale)
01

?
?3470
252:?
70
 
J?44 01
3 G@2: 
 

J
7?6  6
46 <? 7 6 5
 01
6 5
 27H
 (absolute zero) B4<6
 6

M= 
01
5
  J@<6
M= 
 70
2 
J?<?

?4
6
 
01

01
70
2 234 3   
:3 ; 6

M= 
 6
5 4 :  ?
95
?
M=  

B4? 01



4H 
?3470
7

H 34345A01
2H= 01


B4J   

@K
M
N G@2

H 343457601
2 K B4

1. Parametric data 01
3452

H 70 (normal distribution)

502 11 3452

H 70

2. Non parametric data 01
3452

H 7<60

502 12 3452

H 7<60

!Y;D
 Z
[





:0
B4J;BM
C


H
Type of data
Non parametric data
Nominal
Ordinal
Describe one
group
Compare one
group
Compare two
independent
groups
Compare two
dependent
groups
Compare three
or more
independent
groups
Compare three
or more
matched groups
Correlation
between two
variables

Proportion
Chi-square or
Binomial test
Fisher's test
(chi-square
for large
samples)

Parametric data

Survival time

Median,
interquartile range

Mean, SD

Kaplan Meier
survival curve

Wilcoxon test

One-sample t test

Mann-Whitney test

Unpaired t test

Log-rank test or
Mantel- Haenszel

McNemar's test

Wilcoxon test

Paired t test

Conditional
proportional
hazards regression

Chi-square test

Kruskal-Wallis test

One-way ANOVA

Cox proportional
hazard regression

Cochrane Q

Friedman test

Contingency
coefficients

Spearman
correlation

Repeated
measures
ANOVA
Pearson
correlation

Conditional
proportional
hazards regression
-

;;3
3434: 8.?
. P
> : ;K 7
.?
. >: 02
   = 
345

4
0
4
4
 
= 
 
,  
 ? = 
 
7

PH  

0


1.  7H64:

.
 ? ;BM
C
. 3 : 9G
;

 ; 2540.
2. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: the essentaials. 3 rd ed.
Maryland: William&Wilkins; 1996.
3. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002 Jan 26;
359: 34145.
4. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet 2002 Feb 2; 359:
43134.